Expert Interview
Discussing the recent FDA approval of Madrigal Pharma's Rezdiffra, a liver-directed oral therapy that is designed to target key underlying causes of NASH/MASH
Ticker(s): MDGLInstitution: Rutgers University
- Board Certified in Gastroenterology and Internal Medicine
- Distinguished professor of medicine, Director of Hepatology, Professor of Epidemiology, Pathology & and Lab medicine at RU
- Interests include Viral hepatitis, End-stage liver disease, Hepatocellular carcinoma, Fatty liver disease, Autoimmune liver disease, Management of post-liver transplant patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
